Skip to content

Treatment by Therapeutic Body Wraps in Children and Adolescents Suffering From Autism With Severe Injurious Behavior.

Demonstration of the Effectiveness of Treatment by Therapeutic Body Wraps in Children and Adolescents Suffering From Autism Spectrum Disorder With Severe Injurious Behavior.

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03164746
Acronym
PACKING
Enrollment
48
Registered
2017-05-24
Start date
2007-12-01
Completion date
2014-12-01
Last updated
2026-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Spectrum Disorder

Keywords

Autism, Therapeutic body wraps

Brief summary

Severe injurious behaviors in children with autism spectrum disorder are challenging. First line treatment approaches include behavioral techniques but pharmacotherapy is frequently required despite frequent adverse effects in youths. Therapeutic body wraps has been reported in small series or case reports, but has never been assessed in the context of a randomized controlled trial. The present study is an exploratory, multicenter, randomized, controlled, open label with blinded outcome assessment (PROBE design) trial of the effect of wet versus dry therapeutic body wraps in children presenting with autism spectrum disorder and severe injurious behavior.

Detailed description

Packing therapy has never been assessed, namely in children with severe injurious behavior and autism spectrum disorder. The aim of the present study is to evaluate the beneficial effect of wet versus dry therapeutic body wraps through an exploratory randomized controlled open label blinded outcome assessment approach. The primary objective is the comparison of change in ABC irritability scores from baseline to 3 months between the two groups. According to the potential recruitment, we plan to recruit 30 subjects in each group. This sample size could allow us to detect a minimum effect size of 0.74 between the 2 groups (considered large in literature) with a power of 80% (two-sided test and type I error of 5%). As described elsewhere, wet or dry session will be organized through twice-a-week sessions for a 3-month duration. Comparison in primary outcome (ABC irritability score) between the 2 groups will be performed using Analysis of Covariance (ANCOVA) adjusted for the baseline value. The standardized difference (effect size) will be computed taking into account the adjustment for baseline and its 95% confidence interval will be estimated using a bootstrap resampling. The validity of the ANCOVA model will be checked by examining the model residuals. The same methodology will be used for the secondary outcomes.

Interventions

OTHERDry sheet Therapeutic body wraps

At the beginning of the session, the patient's consent to proceed was orally obtained, as no session was compulsory. The therapists checked behavioral manifestations of refusal. Then, the patient was first wrapped in Dry damp sheets (cold phase) and covered up with a rescue and a dry blanket. Afterward the body spontaneously warmed up (warm phase). The patient was then invited to freely express his feelings.

OTHERWET sheet Therapeutic body wraps

At the beginning of the session, the patient's consent to proceed was orally obtained, as no session was compulsory. The therapists checked behavioral manifestations of refusal. Then, the patient was first wrapped in wet damp sheets (cold phase) and covered up with a rescue and a dry blanket. Afterward the body spontaneously warmed up (warm phase). The patient was then invited to freely express his feelings.

Sponsors

University Hospital, Lille
Lead SponsorOTHER
Ministry of Health, France
CollaboratorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
5 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* a current diagnosis of autism, Asperger syndrome, atypical autism according ICD-10 criteria confirmed by specialized clinical assessment; * presenting severe behavioural disturbances such as hetero and self-injurious behaviours, automutilation, severe motor hyperactivity, severe stereotypies. * having a systematically consultation by a neuro pediatric.

Exclusion criteria

* children with known organic syndrome and/or non-stabilized neuropediatric (e.g. seizures) or medical (e.g. diabetes mellitus) comorbidities. * patients with stabilized seizure condition, antiepileptic medication should be stable for at least 4 weeks.

Design outcomes

Primary

MeasureTime frameDescription
Aberrant Behavior Checklist (ABC) irritability scoreBaseline and 3 monthsMeasure the reduction in the intensity of the behavioral disorders objectified by the sub-score Irritability of the scale ABC

Secondary

MeasureTime frameDescription
ABC hyperactivity scoreBaseline,1-month, 2-month and 3-monthsMeasure the reduction in the intensity of the behavioral disorders objectified by the sub-score hyperactivity of the scale ABC
ABC lethargy scoreBaseline,1-month, 2-month and 3-monthsMeasure the reduction in the intensity of the behavioral disorders objectified by the sub-score lethargy of the scale ABC
ABC inappropriate speech scoreBaseline,1-month, 2-month and 3-monthsMeasure the reduction in the intensity of the behavioral disorders objectified by the sub-score inappropriate speech of the scale ABC
ABC stereotypic behavior scoreBaseline,1-month, 2-month and 3-monthsMeasure the reduction in the intensity of the behavioral disorders objectified by the sub-score stereotypic behavior of the scale ABC
ABC Total scoreBaseline,1-month, 2-month and 3-monthsMeasure the reduction in the intensity of the behavioral disorders objectified by the total score of the scale ABC
Child Autism Rating Scale (CARS)Baseline,1-month, 2-month and 3-monthsMeasure the decrease in the intensity of autistic symptoms
Clinical Global Impression-Improvement (CGI-I)Baseline,1-month, 2-month and 3-monthsMeasure the global clinical outcome
Clinical Global Impression-Severity (CGI-S)Baseline,1-month, 2-month and 3-monthsMeasure the global clinical outcome

Countries

France

Contacts

PRINCIPAL_INVESTIGATORPierre Delion, MD, PhD

University Hospital, Lille

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 22, 2026